Comparison of the performance of different HPV genotyping methods for detecting genital HPV types
- 6 May 2008
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 80 (7), 1264-1274
- https://doi.org/10.1002/jmv.21191
Abstract
Classification of high‐risk HPV types for cervical cancer screening depends on epidemiological studies defining HPV type‐specific risk. The genotyping tests that are used, are however, not uniform with regard to type‐specific detection rates making comparisons between different studies difficult. To overcome the lack of a “gold standard” four tests were evaluated crosswise using 824 cervical smears pretested by HC2. The tests evaluated were the L1‐PCR‐based assays PGMY09/11 LBA, HPV DNA Chip and SPF LiPA and an E1 consensus PCR followed by cycle sequencing (E1‐PCR). A subset of 265 samples was tested in addition with the GP5+/6+ reverse line blot assay. Differences were noted in the sensitivity and range for specific HPV types, e.g. with detection rates for HPV53 ranging from 2.3% to 11.6%. HPV16 was the most prevalent type detected by all tests except for the SPF‐10 LiPa, which detected HPV31 more often. Kappa values calculated ranged from poor (k = 0.20) to intermediate (k = 0.54) for HPV positivity, but were higher for high‐risk type positivity (k = 0.31–0.61) and best for recognition of HPV16 (k = 0.53–0.72). The analytical sensitivity of the tests ranged between 15% and 97% for individual types and specificity was highly dependent on which test system was used as “gold standard” for the analysis. The results of histology were used for calculation of clinical sensitivity and specificity. E1‐PCR, PGMY09/11 LBA and SPF‐10 LiPA had a high clinical sensitivity (>95%) for the detection of cervical intraepithelial neoplasia 2 or higher, whereas the HPV DNA Chip reached only 84.1%. J. Med. Virol. 80: 1264–1274, 2008.Keywords
This publication has 25 references indexed in Scilit:
- The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus–Positive, Cytologically Normal Women Over a 10-Year PeriodCancer Research, 2006
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and PreventionJNCI Journal of the National Cancer Institute, 2006
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI Journal of the National Cancer Institute, 2005
- Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic AbnormalitiesJNCI Journal of the National Cancer Institute, 2005
- Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patientsBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerThe New England Journal of Medicine, 2003
- Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up studyBMJ, 2002
- Genotyping of Human Papillomavirus in Liquid Cytology Cervical Specimens by the PGMY Line Blot Assay and the SPF 10 Line Probe AssayJournal of Clinical Microbiology, 2002
- Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human PapillomavirusesThe American Journal of Pathology, 1998